

## Taking action to reduce health inequalities, 13th November 2024

10 00 10 45	Designation refreshments & naturalling
10.00-10.45	Registration, refreshments & networking
10.45-11.00	Chris Walden, CEO, Cancer52
	In his first address as CEO of Cancer52, Chris Walden will set the big themes for the day, and key findings from our latest health inequalities report.
11.00-11.45	Professor Bola Owolabi, Director, National Healthcare Inequalities Improvement Programme, NHS England
	Professor Bola Owolabi will share an update on progress and next steps for NHS England's National Healthcare Inequalities Programme, followed by a Q&A.
11.45-12.30	Panel discussion: Where next for progress on health inequalities for rare and less common cancers?
	<ul> <li>Chair: Sonia Malik, Associate Director of Policy, Influencing &amp; Voice, Young Lives vs Cancer and Chair of Cancer52's Health Inequalities Working Group</li> <li>Professor Francis Chinegwundoh MBE, Chair, Cancer Black Care</li> <li>Ian Vousden, Director, Kent &amp; Medway Cancer Alliance</li> <li>Yvonne Adebola, Executive Group Member, use MY data, and expert by experience</li> <li>Paul Budhan, Head of GI Oncology, AstraZeneca</li> <li>Darcy Bowman, Public Affairs Lead for Oncology and Haematology, Gilead Sciences UK and Ireland</li> </ul>
12.30-1.30	Lunch & networking
1.30-1.45	Launching our health inequalities report
1.00 1.40	
	Jen Harrison, Health Inequalities Lead, Cancer52
1.45-2.30	Hearing from our members
	Lee Dibben, OUTpatients
	Yaser Martini, Team Margot
	Marianne Sladowsky, Wellbeing of Women
	Alison McKinney, WMUK
	Sonia Malik, Young Lives vs Cancer
2.30-3.10	Learning from each other (with refreshments)
	Led by Cancer52 members, a session to critically reflect on their own progress and
	identify shared actions to tackle health inequalities.
3.10-3.50	Have your say on the 10 Year Health Plan for England
	During this session, our Policy Lead Sasha Daly will guide us through an interactive workshop to gather views on the 10 Year Health Plan for England and Cancer Strategy. With invited guests.
3.50-4.00	Closing remarks and next steps Chris Walden, CEO, Cancer52